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Abstract
During menopause, a sharp increase in cholesterol concentration occurs with an unexplained wide variation in change. Possibly, this is
attributable to genetic variation. The authors prospectively studied the effect of the apolipoprotein E (APOE) genotype on the change in
cholesterol level with menopause among 1116 Dutch women. Women with the APOE3E3 genotype were regarded as the reference category
and changes were adjusted for age at baseline, years of follow-up, years since menopause, and body mass index. At baseline, the women
were on average 50.4 years. After 5.9 years of follow-up, the women were on average 4.3 years (S.D. 1.5 years) postmenopausal. The mean
increase in cholesterol with menopause in women with the APOE3E3 genotype was 0.67 mmol/L (95% CI, 0.61–0.72 mmol/L). In women
with the APOE2E3 genotype the increase in cholesterol was 0.44 mmol/L (CI, 0.32–0.56 mmol/L). The increase in cholesterol in women
with the APOE3E4 genotype did not differ from the increase in women with the APOE3E3 genotype. These results show that the increase
in cholesterol level with menopause is 30% lower in women with the APOE2E3 genotype when compared with women with the APOE3E3
genotype, indicating that the APOE genotype contributes to the variation in cholesterol increase with menopause.
© 2004 Elsevier Ireland Ltd. All rights reserved.
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1. Introduction
The incidence of cardiovascular disease in women rises
after middle age. Although still debated[1–4], menopause
is thought to be a determinant of this increase[5–7]. Stud-
ies consistently show that total and low-density lipopro-
tein (LDL) cholesterol are the primary cardiovascular risk
factors affected by menopause[8–17]. Longitudinal stud-
ies show an average increase in total cholesterol with
menopause of 0.5 mmol/L, with a wide variation in change
[18–21]. It is not known why some women have no or only
a slight increase in cholesterol, whereas others exhibit a
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large increase. Possibly, this difference can be explained by
genetic variation.
An important polymorphism associated with cholesterol
level is the apolipoprotein E (APOE) genotype[22]. The
heterogeneity in APOE genotype is responsible for differ-
ent isoforms of apolipoprotein E (apoE), which is mainly
present on chylomicrons and very-low-density lipoproteins
(VLDLs). When associated with these lipoproteins, apoE
serves as a ligand for the hepatic lipoprotein receptors.
It has been firmly established that the APOE polymor-
phism affects plasma cholesterol level. Compared with the
APOE*3 homozygotes, the most common genotype, the
APOE*2 allele is associated with lower levels of choles-
terol, whereas the APOE*4 allele has opposite effects
[22,23]. In a cross-sectional study, the association between
the APOE genotype and cholesterol concentration has been
0021-9150/$ – see front matter © 2004 Elsevier Ireland Ltd. All rights reserved.
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found to be weaker in premenopausal compared with post-
menopausal women[24], suggesting that estrogen affects
the influence of the APOE genotype on cholesterol level.
In a Dutch population-based cohort of women, the Eind-
hoven Perimenopausal Osteoporosis Studies, we examined
prospectively among 1116 women experiencing natural
menopause whether the variation in increase in cholesterol
with menopause may be explained by the APOE genotype.
2. Subjects and methods
2.1. Study population
The Eindhoven Perimenopausal Osteoporosis Study is a
population-based cohort study originally designed to exam-
ine determinants of bone mass, with special emphasis on
gynecological parameters, in perimenopausal women[25].
The baseline examination was conducted between Septem-
ber 1994 and September 1995. All women living in the city
of Eindhoven, The Netherlands, and born between 1941 and
1947 were invited by the Diagnostic Center Eindhoven, a
diagnostic center for general practitioners, and the Depart-
ment of Municipal Public Health Services Eindhoven for
screening of their bone mineral density. Of the 8503 eligible
women, 6700 (79%) participated and gave informed consent
to be invited for future research.
In the year 2000, we selected the population for the cur-
rent study. To prevent admixture we restricted our popula-
tion to the 6448 white Dutch women. Of these, we selected
the 2892 women who were premenopausal, defined as last
menses less than 1 year ago, at the baseline examination
(1994–1995). We excluded women using hormone replace-
ment therapy or oral contraceptives (n = 244) and women
using cholesterol-lowering therapy (n = 21) at baseline be-
cause these medications influence cholesterol levels. Four
women used both types of medication, leaving 2631 women.
Of the 2631 women, 2457 had serum samples at baseline,
208 of whom moved outside the area, leaving 2249 subjects
to be invited for the follow-up study, which was conducted
between November 2000 and May 2001. The study proto-
col was approved by the medical ethics committee of the
Erasmus Medical Center Rotterdam, The Netherlands.
Of the 2249 invited women, 318 did not respond to the
invitation, 68 refused to participate, 8 moved outside the
area after the selection of women to be invited, 12 were
not able to participate because of physical or mental illness,
7 had died, and 7 responded after the ending of the study,
resulting in 1829 participating women, which corresponds
with a participation rate of 81%.
2.2. Interview and clinical examination
At the baseline examination (1994–1995), women were
invited to the Diagnostic Center Eindhoven or the St. Joseph
Hospital in Veldhoven, a suburb of Eindhoven, where infor-
mation on menstruation pattern, menopausal state, and med-
ication use was obtained through an interview by a trained
research assistant. Subsequently, weight and height were
measured, body mass index (BMI, weight divided by height
squared) was computed, and nonfasting blood samples were
taken. Serum samples were obtained and stored at−80◦C
for future use. After the visit, participants were asked to
fill-in a questionnaire on menopausal complaints, smoking
habits, and alcohol use, and return this to the Diagnostic
Center Eindhoven within 1 week (response 92%).
At the follow-up examination (2000–2001) at the Diag-
nostic Center Eindhoven, women were interviewed by a
trained research assistant. Menopausal state was ascertained
by questioning whether the menses had stopped, and if so,
at what age and the reason for its cessation (natural or artifi-
cial). The type of artificial menopause was subsequently reg-
istered. Information on smoking habits and alcohol use was
obtained. Participants were asked to bring their current med-
ication to the research center, where preparation names were
noted (oral contraceptives, hormone replacement therapy,
and cholesterol-lowering medication). Height and weight of
the participants were measured, BMI was computed, and
nonfasting blood samples were taken by venapuncture.
2.3. Cholesterol
Serum samples of the baseline investigation were retrieved
from storage, defrosted at room temperature, and subse-
quently vortexed. Total cholesterol levels of baseline and
follow-up serum samples were assessed in the same batch
o prevent interassay variation contributing to differences
between baseline and follow-up cholesterol levels, with an
automatic enzymatic procedure[26] at the laboratory of the
Diagnostic Center Eindhoven. The interassay coefficient of
variation was 0.49% and the intraassay coefficient of varia-
tion was 0.99% at a level of cholesterol of 7.40 mmol/L.
2.4. DNA isolation and APOE genotyping
EDTA samples obtained at follow-up were frozen at
−20◦C until DNA-isolation and genotyping were per-
formed at the genomic laboratory of the department of
Internal Medicine, Erasmus MC. Genomic DNA was iso-
lated from peripheral leukocytes using PUREGENE® DNA
isolation kit of Gentra Systems (Minneapolis, USA) with
slight modifications of the provided protocol. The extracted
DNA was amplified using a duplex polymerase chain re-




PCRs were carried out in 10l reaction volumes con-
taining 60 ng of genomic DNA, 10*PCR buffer [(Promega)
containing 20 mM Tris-HCl (pH 8.0), 100 mM KCl, 0.1 mM
EDTA, 1 mM DDT, 50% glycerol, 0.5% Nonidet®-P40,
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and 0.5% Tween®20], 1.5 mM MgCl2, 0.2 mM deoxy-NTP,
9 pmol of each ApoE primer, and 1 U of Taq polymerase
(Promega). The reactions were performed in 96-well format
in a thermocycler (MJ-tetrad). Each reaction mixture was
denatured for 5 min at 95◦C and subjected to 35 cycles
of amplification by primer annealing (59◦C for 45 s), ex-
tension (72◦C for 45 s), and denaturation (94◦C for 45 s).
Subsequently, APOE genotyping was performed using the
SNaPshot procedure using primers:
Codon 112: 5′-(T)12 GGGCGCGGACATGGAGGACG-
TG-3′.
Codon 158: 5′-(T)18 CGATGCCGATGACCTGCAGAA-
G-3′.
The SBE reaction was performed according to details
provided by the manufacturer (ABI Prism® SNaPshotTM
ddNTP Primer Extension Kit of PE Biosystems) with slight
modifications of the provided protocol. Samples were an-
alyzed in a random fashion and the laboratory technician
carrying out the genotyping procedures was blinded for the
cholesterol levels of the samples concerned.
2.5. Definition of population for analysis
Of the 1829 women participating at follow-up, 133
women still had a normal menstruation pattern, 357 women
had an irregular menstruation pattern and 1339 women
reported 1 year of amenorrhea. Of these 1339 women,
cessation of the menses had occurred in 70 women after
surgery of the womb and/or ovaries, in five women after
treatment with chemotherapy for breast cancer and in 1264
women spontaneously. We excluded women using hormone
replacement therapy (n = 76) or anti-estrogens (n = 4), and
women using cholesterol-lowering medication (n = 56) at
the time of blood drawing. Two women used two types of
medication, leaving 1130 women. Due to logistic reasons,
cholesterol levels were missing for six women at baseline
and for three women at baseline and at follow-up, leaving
1121 women. DNA isolation was not feasible in blood sam-
ples of five women, resulting in a population for analysis
of 1116 women.
2.6. Statistical analysis
Initially, we used a paired t-test to compare continuous
characteristics measured at baseline and at follow-up, and
the McNemar test for paired comparisons of dichotomous
variables.
We used a general linear model (univariate analy-
sis of variance) to compute and compare mean values
of cholesterol at baseline (premenopausal state) and at
follow-up (postmenopausal state) as well as changes in
cholesterol during follow-up (change with menopause=
follow-up level − baseline level) in strata of the APOE
genotype. In these analyses, the APOE3E3 genotype was
used as reference category. Differences in cholesterol levels
and changes in cholesterol levels relative to the APOE3E3
genotype were tested within the same model with custom
hypothesis testing using a K-matrix. In the analyses at
the premenopausal and postmenopausal state, we adjusted
for age and BMI as measured at premenopausal and post-
menopausal state, by putting these variables as continuous
variables in the model. In models regarding change in
cholesterol with menopause, we adjusted for age at base-
line, years of follow-up, years since menopause, BMI at
baseline, and change in BMI during follow-up (all continu-
ous variables). No interaction terms were used. For missing
data on body mass index the mean value as calculated from
the study population was imputed.
By using analysis of variance (ANOVA) we estimated
the contribution of the APOE genotype to the phenotypic
variation of cholesterol. ANOVA was done on residual val-
ues after adjustment for age and BMI at premenopausal and
postmenopausal assessments. For the analysis regarding the
change of cholesterol, ANOVA was done on residual val-
ues after adjustment for age at baseline, years of follow-up,
years since menopause, BMI at baseline, and change in BMI
during follow-up (all continuous variables). The genotypes
of APOE were entered as dummy variables in the analyses.
We considered two-sided probability-values<0.05 to be
statistically significant. SPSS 10.0 for Windows (SPSS Inc.,
Chicago, Illinois) was used for all analyses.
3. Results
Table 1shows the baseline and follow-up characteristics
of the study population. The mean period of follow-up was
5.9 years (standard deviation [S.D.] 0.3 years) and ranged
from 5.3 to 6.6 years. The mean age at menopause of the
1116 women was 52.1 years and the women were on average
4.2 years postmenopausal (S.D. 1.5 years) at the follow-up
visit. During follow-up, women lost on average 0.8 cm of
their height (S.D. 1.3 cm) and gained 4.0 kg (S.D. 5.3 kg).
At follow-up, fewer women smoked, whereas the propor-
tion of women drinking alcohol had increased compared
with the baseline examination. The mean serum cholesterol
level increased with 0.64 mmol/L (95% confidence interval
[CI]: 0.60, 0.69 mmol/L) during follow-up.Fig. 1shows the
distribution of the change in cholesterol levels in the 1116
women experiencing natural menopause during follow-up.
The distribution of the APOE polymorphism in our study
population was in Hardy–Weinberg equilibrium (χ2 = 3.26;
d.f . = 3; P = 0.35, Table 2). In Table 3, the mean levels
of cholesterol according to menopausal state and changes
in levels of cholesterol during follow-up are shown in
strata of the APOE genotype. Both at premenopausal and
at postmenopausal assessments, age-adjusted cholesterol
levels were intermediate in women with the APOE3E3
genotype, lower in women with the APOE2E3 genotype,
and higher in women with the APOE3E4 genotype. At the
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Table 1
Baseline and follow-up characteristics of 1116 women participating in the Eindhoven Perimenopausal Osteoporosis Studies and experiencing natural
menopause during 5.9 years of follow-up, 1994–1995 to 2000
Characteristic Premenopausal (baseline) Postmenopausal (follow-up)
Age (years) 50.4± 2.2 56.3± 2.1c
Height (m) 1.65± 0.06 1.64± 0.06c
Weight (kg) 68.5± 11.7 72.5± 12.8c
Body mass index (BMI) (kg/m2) 25.3 ± 4.3 27.0± 4.8c
Smoking (%)a 30 26c
Alcohol use (%)b 59 62d
Cholesterol (mmol/L) 5.72± 0.98 6.36± 1.06c
Values are unadjusted mean± S.D. or percentages. At baseline, height was missing in one woman, weight and BMI were missing in four women, and
information on smoking was missing in 129 women (12%). At follow-up, weight and BMI were missing in one woman.
a More than 1 cigarette per day.
b More than 1 glass per week.
c P < 0.001 compared with baseline measurement.
d P < 0.05 compared with baseline measurement.
postmenopausal assessment, cholesterol levels in women
with the APOE2E2 genotype were no longer different
from cholesterol levels in women with the APOE3E3
genotype. By using ANOVA, age and BMI accounted for
approximately 3% of the variance of cholesterol at the
premenopausal and the postmenopausal assessment. The
APOE genotype explained 3.8% of the total phenotypic
variation of cholesterol at the premenopausal assessment
(F5,1110 = 8.78,P < 0.001), whereas at the postmenopausal
assessment it explained 5.8% (F5,1110 = 13.60,P < 0.001),
adjusted for age and BMI.
The mean increase in cholesterol level during menopause
in women with the APOE3E3 genotype was 0.67 mmol/L
(CI: 0.61, 0.72 mmol/L), adjusted for age at baseline, years
of follow-up, years since menopause, BMI at baseline,













Fig. 1. Change in cholesterol levels (mmol/L) in 1116 women participating in the Eindhoven Perimenopausal Osteoporosis Studies and experiencing
natural menopause during 5.9 years of follow-up, 1994–1995 to 2000.
and change in BMI during follow-up. Women with the
APOE2E3 genotype showed a 30% smaller increase of
0.44 mmol/L (CI: 0.32, 0.56 mmol/L) with menopause.
The increase in cholesterol with menopause in women
with the APOE2E2 genotype was 1.45 mmol/L (CI: 0.96,
1.94 mmol/L), although the number of women was low
(n = 9). The increase in cholesterol with menopause in
women with the APOE3E4 or APOE4E4 genotype did
not differ from the increase in women with the APOE3E3
genotype. The change in cholesterol level during follow-up
according to the most common APOE genotypes is visu-
alized in Fig. 2. By using ANOVA, age at baseline, years
of follow-up, years since menopause, BMI at baseline,
and change in BMI during follow-up explained 8.2% of
the change in cholesterol level with menopause. Adjusted
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Table 2
Distribution of APOE genotypes and allele frequencies in 1116 women
participating in the Eindhoven Perimenopausal Osteoporosis Studies and
experiencing natural menopause during 5.9 years of follow-up, 1994-1995
to 2000











This study includes Dutch white women only.
a χ2 Hardy–Weinberg distribution is 3.26; d.f . = 3; P = 0.35.
for these variables, the APOE genotype explained 2.6%
of the variation of cholesterol increase with menopause
(F5,1110 = 5.99, P < 0.001).
4. Discussion
Our results among 1116 women experiencing natural
menopause show that the increase in cholesterol level dur-
ing menopause is statistically significantly 30% lower in
women with the APOE2E3 genotype when compared with
women with the APOE3E3 genotype.
In the current large population-based study, we were able
to measure intraindividual changes in cholesterol levels in
women experiencing natural menopause. The increase in
cholesterol was similar to previously described changes in
early postmenopausal women[21]. The largest increase in
cholesterol with menopause occurs in the perimenopausal
years [21]. Because we included women on average 1.7
years before the cessation of their menses we were able to
adequately monitor the menopausal increase in cholesterol.
The increase in cholesterol level with menopause is most
Table 3
Mean levels of cholesterol (95% CI) (mmol/L) according to APOE genotype in 1116 women participating in the Eindhoven Perimenopausal Osteoporosis
Studies and experiencing natural menopause during 5.9 years of follow-up, 1994–1995 to 2000








All women 1116 5.72 (5.66; 5.77) 6.36 (6.30; 6.42) 0.64 (0.60; 0.69) 12.3 (11.4; 13.1)
E2E2 9 4.97 (4.33; 5.60)c 6.31 (5.62; 6.99) 1.45 (0.96; 1.94)c 34.0 (24.9; 43.1)c
E2E3 147 5.37 (5.21; 5.52)c 5.81 (5.64; 5.97)c 0.44 (0.32; 0.56)c 9.2 (6.9; 11.4)c
E2E4 25 5.37 (4.99; 5.74) 5.92 (5.51; 6.33)c 0.55 (0.26; 0.84) 11.8 (6.5; 17.2)
E3E3 (reference) 687 5.73 (5.66; 5.80) 6.39 (6.32; 6.47) 0.67 (0.61; 0.72) 12.6 (11.6; 13.7)
E3E4 221 5.91 (5.79; 6.04)c 6.62 (6.49; 6.76)c 0.71 (0.61; 0.80) 12.6 (10.8; 14.4)
E4E4 27 6.18 (5.81; 6.54)c 6.87 (6.48; 7.26)c 0.71 (0.43; 0.99) 13.1 (7.8; 18.3)
a Adjusted for age and body mass index.
b Adjusted for age at baseline, years of follow-up, years since menopause, body mass index at baseline, and change in body mass index during follow-up.
c Statistically significantly different from APOE3E3 (P < 0.05).
pronounced for LDL cholesterol[20]. Because measures
of LDL cholesterol were not available in our study, we
used total cholesterol, which is strongly associated with
LDL cholesterol. Since any misclassification of cholesterol
level is expected to be nondifferential across genotypes,
it will not have biased our results. We excluded women
using lipid-lowering medication at premenopausal or post-
menopausal assessments. APOE*4 carriers are known to
have higher cholesterol levels[22,23], therefore, we may
preferentially have excluded women carrying this allele.
Whereas all women in our study experienced menopause,
the increase in cholesterol level was different among strata
of the APOE genotype, indicating that the APOE geno-
type contributes to the variation in change of cholesterol
with menopause. From cross-sectional data among pre-
menopausal and postmenopausal women it was inferred
that the increase in cholesterol with menopause would
be 9% among women with the APOE2E3 genotype[24],
which is similar to our results. Also, the increase in choles-
terol with menopause was inferred to be similar in women
with the APOE3E3 or APOE3E4 genotype[24]. In the
Healthy Women Study, no effect of the APOE genotype
on differences in changes in cholesterol level was ob-
served between women who became postmenopausal and
age-matched women who stayed premenopausal during
3.5 years of follow-up[27]. However, only 12 and 18
postmenopausal women, respectively, were present in the
APOE2E3 and APOE3E4 genotype groups. Furthermore,
cholesterol concentration increases from perimenopause on-
ward. Comparing postmenopausal women with age-matched
premenopausal women[27], of whom some will be per-
imenopausal, may therefore lead to an underestimation
of the effect of menopause. Also in this study[27], the
lower values of cholesterol for women with the APOE2E3
genotype were maintained through menopause despite an
increase in cholesterol levels.
In the Framingham Offspring Study, the association
between the APOE genotype and cholesterol concentra-
tion was absent in premenopausal women, whereas it was
present in postmenopausal women[24], suggesting that the
decrease in estrogen level at the time of menopause fully























Fig. 2. Change in cholesterol levels (mmol/L)* according to APOE genotype in 1055 women participating in the Eindhoven Perimenopausal Osteoporosis
Studies and experiencing natural menopause during 5.9 years of follow-up, 1994–1995 to 2000. Symbol (*) denotes the values adjusted for age at baseline,
years of follow-up, and years since menopause and (†) women with the E2E2 (n = 9), E2E4 (n = 25), or E4E4 (n = 27) genotype are excluded.
unmasks sensitivity to the effects of the APOE genotype.
In our study, we found the APOE genotype to be associ-
ated with cholesterol level at both the premenopausal and
the postmenopausal assessment. Therefore, our results do
not entirely support the hypothesis that menopause un-
masks genetic susceptibility to the effects of the APOE
genotype. However, also in our study the contribution of
the APOE genotype to the total phenotypic variation of
cholesterol tended to be higher in postmenopausal women
than in premenopausal women, indicating that the effect
of the APOE genotype on cholesterol level is amplified by
menopause.
Although the number of women with the APOE2E2 geno-
type in our study was small (n = 9), women with this
genotype displayed a very large increase in cholesterol level
with menopause. Homozygosity for the APOE*2 allele is a
very common, albeit not sufficient, cause for type III hyper-
lipoproteinemia (type III HLP), which is characterized by
both hypercholesterolemia and hypertriglyceridemia[28].
Even though the frequency of the APOE2E2 genotype is
about 1 in 100 in the general population, as in our study
population, the disorder occurs only about 1 in 5000[28].
Additional metabolic factors are usually required for full
clinical expression[29]. Menopause is considered to be a
factor contributing to the expression of this disorder[30,31],
which gives support for the hypothesis that estrogen modi-
fies the effect of the APOE genotype on cholesterol level.
The beneficial response of cholesterol to hormone re-
placement therapy in early postmenopausal women has also
been found to be related to the APOE genotype[32,33]. In
Finnish[32] and Japanese[33] postmenopausal women, the
cholesterol-lowering effect of hormone replacement therapy,
as studied in a randomized controlled trial design, was ab-
sent in women carrying the APOE*4 allele[32,33]. In the
Japanese study[33], results were presented separately for
women with the APOE2E3 or the APOE3E3 genotype. The
cholesterol-lowering effect of hormone replacement therapy
was most pronounced in women with the APOE2E3 geno-
type [33]. Also in our study, women with the APOE2E3
genotype showed statistically significantly different changes
in cholesterol during follow-up when compared with women
with the APOE3E3 genotype. Together with our results,
these results suggest that estrogen modifies the effects of the
APOE genotype on cholesterol level.
The mechanism relating menopause to the increase in
cholesterol level is primarily thought to be due to a reduc-
tion in LDL receptor number or activity in response to the
decline in blood estrogen level[34]. Although our data indi-
cate that the APOE genotype contributes to the variation in
increase in cholesterol with menopause, the variation is far
from completely explained by the APOE genotype. Other
factors, such as expression of estrogen receptors, which me-
diate the activation of the LDL receptor in the liver[35], may
be involved in the increase of cholesterol with menopause.
Studies on the association between the APOE geno-
type and either atherosclerosis or cardiovascular disease
have shown inconsistent results[36–39]. However, few
population-based investigations including women have been
performed on this topic. In a Dutch population-based study,
the APOE2E3 genotype was inversely related to carotid
artery atherosclerosis in elderly men and women[40]. This
result agrees with the results of our study, which showed
the increase of cholesterol level during follow-up to be
lowest in women with the APOE2E3 genotype. Although
cholesterol level was not an intermediate in the association
between APOE genotype and carotid atherosclerosis[40],
it seems reasonable to speculate that the amount of change
of cholesterol with menopause would have an impact on the
development or progression of atherosclerosis and cardio-
vascular disease. In the Healthy Women Study, the amounts
of coronary and aortic atherosclerosis measured shortly af-
ter menopause were not found to be related to changes in
levels of LDL cholesterol with menopause[41]. However, a
longer follow-up time may be necessary for effects of higher
cholesterol levels on atherogenesis to become detectable.
In conclusion, our results in 1116 women experiencing
natural menopause show that the increase in cholesterol level
with menopause is 30% lower in women with the APOE2E3
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genotype when compared with women with the APOE3E3
genotype, indicating that the APOE genotype contributes to
the variation in the increase in cholesterol with menopause.
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